Biofrontera (BFRI) Cost of Revenue (2020 - 2025)

Biofrontera's Cost of Revenue history runs 6 years deep, the most recent figure standing at $3.0 million for Q4 2025.

• In Q4 2025, Cost of Revenue fell 42.91% year-over-year to $3.0 million; the TTM figure through Dec 2025 stood at $11.0 million (down 41.07% YoY), while the FY2025 annual figure was $11.0 million, down 41.08% from the prior year.
• Cost of Revenue was $3.0 million for Q4 2025 at Biofrontera, up from $2.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $17.5 million in Q4 2022 to a low of -$1.4 million in Q4 2023.
• Historically, Cost of Revenue has averaged $2.9 million across 5 years, with a median of $2.7 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue surged 9554.7% in 2022, then plunged 107.76% in 2023.
• A 5-year view of Cost of Revenue shows it stood at $181000.0 in 2021, then soared by 9554.7% to $17.5 million in 2022, then slumped by 107.76% to -$1.4 million in 2023, then surged by 488.72% to $5.3 million in 2024, then plunged by 42.91% to $3.0 million in 2025.
• The last three Cost of Revenue figures came in at $3.0 million (Q4 2025), $2.0 million (Q3 2025), and $2.6 million (Q2 2025), per Business Quant data.